Effects of Genotype on Resting State Connectivity During Methamphetamine Administration
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
Addiction to methamphetamine (MA) is a serious health problem in the United States. Right
now, there are no medically approved treatments for MA dependence. More research is needed to
understand how MA affects the brain and to eventually develop medical interventions for MA
addiction. The purpose of the study is to learn more about how MA use affects the brain by
investigating a receptor in the brain called trace amine-associated receptor 1 (TAAR1). The
investigators are hoping to find out if individuals with certain versions of the brain
receptor react differently when given MA. The TAAR1 receptor has two prevalent genetic
variations due to a single nucleotide polymorphism. These are the wild type (WT) and a common
variant (CV). Preliminary studies have shown that these variants produce different
connectivity (resting state functional connectivity or RSFC) in the brains of individuals
with MA use disorder (MUD), specifically that individuals with the CV genotype exhibit lower
RSFC than WT. In this study, MA will be administered to individuals with MA use disorder and
healthy controls in order to:
1. Determine the influence of CV vs. WT genotype on RSFC and craving in individuals with
chronic MUD and healthy controls.
2. Determine the effect of acute methamphetamine or placebo administration on the
interaction of CV vs WT genotype on RSFC, craving, cognitive control, attention and
subjective experience in MUD and healthy controls.